Related Experiment Videos
Decision analysis: MIBI imaging of nonpalpable breast abnormalities
1Department of Internal Medicine and Massey Cancer Center, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0170, USA.
Summary
Sestamibi imaging and core biopsy offer significant cost savings for evaluating breast lesions compared to surgery, with a slight trade-off in early cancer detection. These noninvasive strategies may reduce costs by up to 39% while avoiding invasive procedures for many women.
Area of Science:
- Medical Imaging
- Oncology
- Health Economics
Background:
- Scintimammography using sestamibi shows promise for evaluating suspicious breast lesions.
- Noninvasive breast evaluation strategies are being explored to improve patient outcomes and reduce healthcare costs.
Purpose of the Study:
- To guide future studies and evaluate clinical/financial consequences of noninvasive breast evaluation strategies.
- To compare sestamibi breast imaging, stereotactic core biopsy, and surgical biopsy for nonpalpable breast lesions using decision analysis.
Main Methods:
- A decision analysis model simulated 1000 women with nonpalpable breast lesions.
- Compared sestamibi imaging, core biopsy, and surgical biopsy, estimating sensitivity and specificity from literature.
- Calculated costs based on institutional data and sestamibi projections, including 6-month follow-up for negative results.
Main Results:
- Core biopsy missed 7 invasive and 10 in situ cancers per 1000 women compared to surgery.
- Sestamibi imaging missed an additional 16 invasive and 12 in situ cancers compared to core biopsy.
- Sestamibi strategy reduced costs by 39% and core biopsy by 20% versus surgery; 65% avoided invasive biopsy with sestamibi.
Conclusions:
- Sestamibi imaging or core biopsy offer substantial cost savings versus surgery with a minor compromise in early cancer detection.
- Decision analysis aids in designing trials for new strategies.
- Adoption depends on confirming test characteristics, understanding delayed diagnosis natural history, and patient preferences regarding avoiding biopsy.